Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiency-related ichthyosis in a child.

Author: FuxM, GautschiM, GouveiaC, HäfligerS, IypeJ, NuofferJ M, SchallerA, YogarajahJ

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

Patients with severe autosomal recessive congenital ichthyosis (ARCI) experience a heightened inflammatory response. This study suggests that secukinumab, an IL-17A inhibitor, could potentially be effective in treating ARCI due to its efficacy in psoriasis, which shares a similar inflammatory profile.
Paper Details　
Original Abstract of the Article :
Patients with severe autosomal recessive congenital ichthyosis (ARCI) show a T helper 17/interleukin 17 (Th17/IL17) skewing in their skin and serum, resembling the inflammatory profile of psoriatic patients. Secukinumab, an IL-17A inhibitor, has shown clinical efficacy in patients with moderate-to-s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060064/

データ提供：米国国立医学図書館（NLM）

Secukinumab for Severe Ichthyosis

[Autosomal recessive congenital ichthyosis (ARCI)] is a rare and challenging skin condition. This study investigates the potential of [secukinumab], an [interleukin 17A (IL-17A) inhibitor], for the treatment of [severe ARCI]. The research focuses on [clinical efficacy and safety] of this medication in a [pediatric patient].

Secukinumab: A Promising Option for Ichthyosis?

The study demonstrates that [secukinumab] may offer [clinical efficacy] in the treatment of [severe ARCI]. The medication's mechanism of action, targeting [IL-17A], a key inflammatory mediator in [ARCI], aligns with the disease's underlying [inflammatory profile].

Treating Ichthyosis: A Personalized Approach

While the results suggest a potential role for [secukinumab] in [treating ARCI], it's crucial to remember that [individualized treatment] is key. This research highlights the importance of carefully considering the [benefits and risks] of this medication in each patient, taking into account their specific clinical presentation. It's like finding a suitable oasis in the desert – the best approach depends on the individual's needs and the surrounding environment.

Dr. Camel's Conclusion

This research on secukinumab for ichthyosis is like a camel caravan discovering a potential new source of water in a barren desert. The findings suggest a promising avenue for treating this challenging condition. However, a cautious approach, like a camel navigating a desert with expertise, is essential to ensure safety and efficacy for each patient.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-02-21
Further Info :

Pubmed ID

35664977

DOI: Digital Object Identifier

PMC9060064

Related Literature

Article Analysis
・Effects of secukinumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.